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Clinical outcome of children with malignant glioma remains dismal. Here, we examined the role of over-expressed
BMI1, a regulator of stem cell self-renewal, in sustaining tumor formation in pediatric glioma stem cells. Our
investigation revealed BMI1 over-expression in 29 of 54 (53.7%) pediatric gliomas, 8 of 8 (100%) patient derived
orthotopic xenograft (PDOX) mouse models, and in both CD133+ and CD133− glioma cells. We demonstrated that
lentiviral-shRNA mediated silencing of suppressed cell proliferation in vitro in cells derived from 3 independent PDOX
models and eliminated tumor-forming capacity of CD133+ and CD133− cells derived from 2 PDOX models in mouse
brains. Gene expression profiling showed that most of the molecular targets of BMI1 ablation in CD133+ cells were
different from that in CD133- cells. Importantly, we found that silencing BMI1 in CD133+ cells derived from 3 PDOX
models did not affect most of the known genes previously associated with the activated BMI1, but modulated a
novel set of core genes, including RPS6KA2, ALDH3A2, FMFB, DTL, API5, EIF4G2, KIF5c, LOC650152, C20ORF121,
LOC203547, LOC653308, and LOC642489, to mediate the elimination of tumor formation. In summary, we identified
the over-expressed BMI1 as a promising therapeutic target for glioma stem cells, and suggest that the signaling
pathways associated with activated BMI1 in promoting tumor growth may be different from those induced by silencing
BMI1 in blocking tumor formation. These findings highlighted the importance of careful re-analysis of the affected genes
following the inhibition of abnormally activated oncogenic pathways to identify determinants that can potentially
predict therapeutic efficacy.Introduction
Tumors of the central nervous system are the second
most common cancer in children. Glioblastoma multi-
forme (GBM) is one of the most malignant brain tumors
that occur both in children and adults. The primary
treatment for GBM is surgical resection followed by* Correspondence: xiaonan@bcm.tmc.edu
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unless otherwise stated.chemotherapy and radiotherapy [1,2]. Overall survival
for pediatric GBM (pGBM) patients remains poor, with
5-year survival rates of <20% [1]. Even in long-term sur-
vival patients, many children are left with significant
physical and neuropsychological sequelae caused by
therapy-related toxicities. Better understanding of tumor
biology is needed for the development of new and more
effective therapies.
Recent isolation of cancer stem cells (CSCs), also
termed tumor-initiating cells [3-8], has created a new
conceptual model for examining tumorigenesis and treat-
ment failure. CSCs were shown to be resistant to standard
chemotherapies and/or radiotherapies, causing tumorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cure disease. Many of the fundamental properties of
CSCs are shared with normal stem cells [14,15]. Among
them, the capability of self-renewal [3,4,15] plays the
most important role in sustaining tumor growth. There-
fore, genes and genetic pathways promoting abnormal
self-renewal in CSCs should be prioritized for therapeutic
targeting.
BMI1, a member of the polycomb group gene family,
is an important regulator of self-renewal of
hematopoietic and neural stem cells [16-19]. Mouse
Bmi1 was initially identified as a collaborator of c-myc
[20,21]; and down-regulates p16 (Ink4a) and p19 (Arf)
[17,22]. Over-expression of BMI1 has been reported in
many different human cancers, including medulloblas-
toma [23-25] and adult GBM [26-28]. High level of
BMI1 is associated with medulloblastoma invasion [29]
and is also considered to be a poor prognostic marker
in multiple human cancers [30-34], and is significantly
involved in chemoresistance and tumor recurrence
[35-38]. An 11-gene signature associated with the activated
BMI1 was identified, and it reliably predicated shorter
interval to recurrence and poor prognosis in 11 types of
human cancers [39].
Several studies have shown that BMI1 is indispens-
able for self-renewal of normal and cancer stem cells
[16,23,27]. The expression status and the functional
roles of BMI1 in pGBMs stem cells, however, remain
unknown. Additionally, while the genes and pathways
associated with over-expressed BMI1 have been fre-
quently reported, little is known about the genetic
changes after the high level expression of BMI1 is
knocked down in CSCs. Specifically, it is still not clear
if silencing the aberrantly activated BMI1 in CSCs will
affect the known target genes to reverse the pheno-
type; or if a new set of genes will be regulated to mediate
the biological changes. Because there is increasing inter-
est in developing targeted therapies against BMI1 [40],
and integrated genetic analysis have revealed key dif-
ferences between pediatric and adult GBM [41-44], it
is important to determine the role of BMI1 in pGBM
CSCs.
In this study, we examined if BMI1 is over-expressed
in pediatric gliomas of various pathologic grades and if
the over-expression of BMI1 was replicated in our new
panel of 8 patient tumor-derived orthotopic xenograft
(PDOX) mouse models. Using this set of clinically relevant
animal models, we further examined if BMI1 expression
was restricted to CD133+ cells, and if silencing BMI1
would significantly suppress cell proliferation in vitro and
eliminate tumor formation in vivo. To understand the
underlying molecular mechanisms, we performed global
gene expression profiling in paired CD133+ and CD133−
cells and examined if it was the known targets or somenew genes that were critical to the biological changes in-
duced by silencing BMI1.
Materials and methods
Pediatric glioma tumors
Freshly resected pediatric brain tumor specimens were
collected from 48 children undergoing surgery at Texas
Children's Hospital, and 6 patients at the University of
Michigan Medical School (Figure 1). Signed informed
consent was obtained from the patient or their legal
guardian prior to sample acquisition in accordance with
local institutional review board (IRB) policy.
Orthotopic transplantation into SCID mice
Surgical transplantation of tumor cells into mouse cere-
brum and cerebellum was performed as we described
previously [45,46], following the Institutional Animal
Care and Use Committee (IACUC) approved protocol.
Briefly, mice (aged 6–8 weeks of both sex) were anesthe-
tized with sodium pentobarbital (50 mg/kg). Tumor cells
(1 × 105 for fresh surgical specimens, 1.5 × 103 cells for
CD133+ cells, and 1 × 104 for CD133− cells) were sus-
pended in 2 μL of culture medium and injected into the
cerebral hemisphere (1 mm to the right of the midline,
1.5 mm anterior to the lambdoid suture and 3 mm deep)
via a 10-μL 26-gauge Hamilton Gastight 1701 syringe
needle. Tumor cells from IC-1227AA, which was derived
from a cerebellar anaplastic astrocytoma [45], were im-
planted to mouse cerebellar hemisphere (1 mm to the
right of the midline, 1 mm posterior to lambdoid suture
and 3 mm deep). The animals were monitored daily until
they developed signs of neurological deficit or became
moribund. They were then euthanized and their brains
removed for histopathological analysis [45,46].
Lenti-viral shRNA
Mission® shRNA Lentiviral transduction particles were
obtained from Sigma-Aldrich. Five different Lentiviruses
were obtained and screened for gene silencing efficacy.
Listed below are the shRNA sequences. Lenti-BMI1-938:
CCGGC GGAAA GTAAA CAAAG ACAAA CTCGA
GTTTG TCTTT GTTTA CTTTC CGTTT TT; Lenti-
BMI1-1061: CCGGC CTAAT ACTTT CCAGA TTGAT
CTCGA GATCA ATCTG GAAAG TATTA GGTTT
TT; Lenti-BMI1-693: CCGGC CAGAC CACTA CTGAA
TATAA CTCGA GTTAT ATTCA GTAGT GGTCT
GGTTT TT; Lenti-BMI1-1134: CCGGC CTACA TTTAT
ACCTG GAGAA CTCGA GTTCT CCAGG TATAA
ATGTA GGTTT TT; Lenti-BMI1-922: CCGGC CAGAA
CAGAT TGGAT CGGAA CTCGA GTTCC GATCC
AATCT GTTCT GGTTT TT. Lentiviruses expressing
GFP (Lenti-GFP) were used to monitor transduction effi-
ciency, and those containing no shRNA or non-target
shRNA (Lenti-sh) were included as controls.
010
20
30
40
50
60
N
FC NF
B
N
FC NC
2
34
4
18
4
14
5
14
6
35
93 15
7
14
4
13
0
11
7
67
96
36
48 12
4
12
3
12
0
45
24 17
0
31
6
14
9
17
2
10
4
11
0
15
9
10
3
13
5
23
54 13
6
35
26
28
79
69
37 21
0
15
6
12
8
12
1
10
8
37
52
-P
t
37
04
-P
t
M
U-
01
10
17
9
14
06
-P
t
14
66
A4
6-
Pt
M
U-
02
19
23
05
-P
t
M
U-
30
7
63
14
64
40
49
33
M
U-
05
19
31
03
M
U-
01
15
M
U-
05
11
Normal          AST                                        JPA                                  EPN
GBM
%
  (B
MI
-1/
GA
PD
H
)
0
5
10
15
20
25
30
35
Pt tum
Xeno-I
Xeno-III
Xeno-V
%
  (B
MI
-1/
GA
PD
H
)
Pt
  t
um
Xe
n
o
-I
Xe
n
o
-II
I
Pt
  t
um
Xe
n
o
-I
Xe
n
o
-V
I
Pt
  t
um
Xe
n
o
-I
Xe
n
o
-II
I
Xe
n
o
-V
I
Pt
 tu
m
Xe
n
o
-I
Xe
n
o
-II
I
Xe
n
o
-V
I
Xe
n
o
-I
Xe
n
o
-II
I
Xe
n
o
-
V
Xe
n
o
-I
Xe
n
o
-II
I
Xe
n
o
-
V
Xe
n
o
-I
Xe
n
o
-
V
Xe
n
o
-I
Xe
n
o
-II
I
3704               3752                1621             1502   1406              2305                1128          1227
A
B
IC‐2305GBMIC‐1406GBMIC‐3704GBM IC‐3752GBM
C
D
ytivitisoP1-IMB)+++(hgiHytivitisoP1-IMB)+(woL
BMI‐1
Beta‐actin
N
or
m
al
37
04
37
52
 
16
21
15
02
14
06
23
05
11
28
12
27 DAPI CD133    BMI-1 merge
CD
13
3+
   
   
CD
13
3-
E
Figure 1 (See legend on next page.)
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Figure 1 Expression of BMI1 in pediatric gliomas. (A) Analysis of BMI1 mRNA in pediatric brain astrocytomas (AST), juvenile pilocytic astrocytoma
(JPA), ependymoma (EPN) and glioblastoma (GBM) using qRT-PCR. The relative levels of BMI1 were normalized to an internal control GAPDH and
expressed as a percentage (mean ± SD). Red dotted lines indicate the levels of normal adult cerebral tissues. (B) BMI1 mRNA expression in the 8 PDOX
mouse models. The relative levels of xenograft tumors during serial sub-transplantations from passage I to V (xeno-I to xeno-V) as well as the original
patient tumors (Pt tum) (if available) were quantitated with qRT-PCR. (C) Representative immunohistochemical staining showing the GBM xenograft
models with low-medium (IC-3704GBM and IC-3752GBM) and high BMI1 protein expressions (arrows) (IC-1406GBM and IC-2305GBM). (D) Western
hybridization showing the increased BMI1 protein expression in the 8 GBM xenograft mouse models using beta-actin as loading control. Note that
BMI1 protein was not expressed in the normal adult cerebral tissue, and the relative levels of BMI1 protein in the 8 xenograft models appeared to be
correlated with their relative mRNA expressions, particularly in those with high mRNA transcripts (1406, 2305, 1128, and 1227). (E) Immunofluorescent
staining showing that BMI1 protein was expressed in FACS-purified CD133+ and CD133- xenograft cells derived from ICb-1227AA.
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Xenograft tumor cells were incubated with serum-free
media, containing Neurobasal medium, bFGF (50 ng/mL),
EGF (40 ng/mL), N2, and B27 (Invitrogen) [45,46]. Lentivi-
ruses carrying non-target shRNA or BMI1-specific shRNA
were added to cell suspension (MOI =1). Cell proliferation
was measured 2 weeks later with a cell counting kit (CCK)
(Dojindo) as described previously [45,46].
Western hybridization
Proteins were extracted from the xenograft tumors with
Trizol (Invitrogen), and cells transduced with Lenti-
shRNAs with Mammalian Protein Extraction agent (Piece)
following the manufacturer’s instructions. Protein concen-
trations were assessed with the Bio-Rad DC protein assay
kit. Equal amounts of protein were loaded onto Invitrogen
4-12% Bis-Tris gel. Proteins were then transferred onto
PVDF membrane (Bio-Rad), blocked with 5% non-fat dry
milk, and blotted with mouse monoclonal antibodies
against BMI1-1 (05–637, MILLIPORE) and actin (3700S,
Cell Signaling) followed by goat anti–mouse IgG-HRP
(sc-2031, Santa Cruz) antibodies, respectively. The sig-
nals of actin and BMI1 were detected using ECL Substrate
(Pierce).
Quantitative real-time RT-PCR (qRT-PCR)
This was performed with SYBR green master mix in an
ABI 7000 DNA detection system (ABI, Columbia, MD)
as we previously described [47]. Complementary DNA
was synthesized with MuLV reverse transcriptase and
random hexamers (Perkin Elmer, Foster City, CA) in a
total volume of 20 μl from 1 μg of total RNA extracted
with TRIzol reagent (Invitrogen, Carlsbad, CA). Primers
for PCR amplification were designed. Expression levels
of the selected genes were normalized first to the in-
ternal standard GAPDH followed by normalization to
lenti-non-target-shRNA using the standard ΔΔCt
method [46]. All reactions were performed in duplicate
and repeated twice. The specificities of PCR products
were confirmed by analyzing dissociation curves from
individual reactions and visualizations on 2% agarose
gel.Immunohistochemical (IHC) Staining
IHC staining was performed using a Vectastain Elite kit
(Vector Laboratories, Burlingame, CA) as described pre-
viously [48]. In brief, antigen retrieval was performed in
a microwave oven in 0.03 M sodium citrate acid buffer.
Endogenous peroxidase was quenched using hydrogen
peroxide before sections were blocked in avidin D and
biotin blocking reagent. After slides were incubated with
monoclonal antibodies against BMI1-1 (MILLIPORE)
(1:300) for 90 minutes at room temperature, the appro-
priate biotinylated secondary antibodies (1:200) were ap-
plied and incubated for 30 minutes, and the final signal
was developed using the 3,3'-diaminobenzidine (DAB)
substrate kit for peroxidase. For negative staining con-
trol, primary antibodies were replaced by PBS.
Florescence activated cell sorting (FACS)
Xenograft tumor cells were incubated with monoclonal
antibodies against CD133 that were conjugated with PE
or APC at 4°C for 10 minutes, followed by flow sorting
with MoFlo system. The dead cells were excluded with
the use of propidium iodide (PI) staining.
Immunofluorescence staining
The FACS-purified CD133+ and CD133− cells were spread
on positively charged slides, fixed with paraformaldehyde,
and subjected to immunofluorescent staining using the
Double Labeling Immunofluorescent Detection System
(Lab Vision). Then, the antibodies against BMI1 and ap-
propriate second antibodies were applied and detected
with avidin conjugated with FITC. The images were cap-
tured with Pathvysion using a Nikon fluorescence micro-
scope with a color CCD camera attached.
Whole-genome gene expression profiling
The genome-wide expression analysis was performed
using Illumina's Human-6 v2 BeadChips, which contains
more than 48 K transcript probes, following manufactur-
er's instructions. Briefly, total RNA was extracted with
TRIzol reagent (Invitrogen, Carlsbad, CA) as described
previously [47]. RNA concentrations were measured
using a Nanodrop 1000 spectrophotometer. RNA
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ose gel with 6% formaldehyde. A half-microgram of total
RNAs was used to synthesize biotinylated cRNA using
Totalprep RNA amplification kit (Ambion Inc, Austin,
TX), and 1.5 μg of biotinylated cRNA was applied to the
HumanWG-6 v2 Beadchips and processed according to
the vendor’s instructions (Illumina, San Diego, CA).
Each sample was loaded in duplicates on the chips. The
Beadchips were scanned using a Beadstation 500 GX
scanner.
The raw image files from the scanner were imported
into the Bead Studio software Gene Expression module
version 3.2.7 (Illumina Inc., San Diego, CA) and were
processed using the quantile normalization algorithm.
This method assumed that the distribution of the ex-
pression values did not change dramatically between ar-
rays. All arrays were adjusted so that they showed an
almost identical intensity distribution from all the genes.
All 42620 elements in the gene profile tab in Bead Studio
were used in the normalization. The log intensity values
were analyzed in Bioconductor [49].
The differentially expressed genes were identified by
comparing the normalized signal intensities induced
by Lenti-BMI1-693 and Lenti-BMI1-922 with those by
the non-target Lenti-shRNA through paired Student t
test. P <0.05 and log2 fold changes >0.5 or < −0.5 was
set as the cutoff for differentially expressed genes.
Those genes whose expression was altered by the
non-target Lenti-shRNA (P <0.05 and log2 fold
changes >0.5 or < −0.5 when compared with the un-
treated control) were subtracted from the list. Heat-
maps of different sets of the differentially expressed
genes were created using average Pearson correlation
and average linkage method implemented by the
Multi-Experiment Viewer.
Statistical analysis
Analysis of animal survival times was performed using
log-rank analysis followed by pair-wise comparisons with
the Holm-Sidak method and graphed with SigmaPlot 11
(Systat Software, Inc., San Jose, CA).
Results
Elevated expression of BMI1 mRNA in pediatric malignant
gliomas
To determine the mRNA expression of BMI1 in pediatric
gliomas, we applied qRT-PCR in a panel of 54 pediatric
gliomas. Due to the difficulties of obtaining age-matched
normal human cerebral tissues, normal RNA from 2 fetal
brains, 1 adult cerebrum, and pooled RNA from 10 nor-
mal cerebrums (Clontech) were included as controls. The
expression levels of BMI1 mRNA were normalized to that
of GAPDH [46]. As expected, the BMI1/GAPDH ratio
was higher in the fetal brains (12.3 ± 0.9%) than that in theadult cerebral tissues (7.1 ± 1.16%). When the BMI1/
GAPDH levels in the pediatric brain tumors were normal-
ized with that of the normal adult cerebral tissues, ele-
vated BMI1 expression (>1.5 fold of adult cerebral tissues)
was observed in 8 of 15 (53.3%) astrocytomas (2.3 ± 0.3
folds), 8 of 14 (57.1%) juvenile pilocytic astrocytomas
(JPAs) (2.4 ± 1.2 folds), 3 of 5 (60%) ependymomas
(2.18 ± 1.5 folds), and 10 of 17 (58.8%) GBMs (3.55 ± 1.1
folds). Further comparison with the fetal brains identified
2 of the 14 (14.2%) JPAs and 7 of the 17 (41.2%) GBMs
that exhibited increased BMI1 expression (>1.5 fold of that
in the fetal brains), a phenomenon that was not found
in any of the 15 astrocytomas or the 5 ependymomas
(Figure 1A). Combined, these data suggested that over-
expression of BMI1 mRNA occurred in ~50% of pediatric
brain tumors (compared with normal adult cerebral
tissues), and pGBMs tend to have higher levels than that in
the low-grade gliomas.
Preservation of BMI1 over-expression in PDOX
mouse models
To test the functional roles of BMI1 in pGBM, it is de-
sirable to have clinically relevant pGBM mouse models
that over-express BMI1. We have previously shown
that primary-tumor derived orthotopic xenograft mouse
models replicated the histology, invasive growth, and
genetic abnormalities of pediatric brain tumors [45,50].
To further determine if BMI1 expression was replicated,
we examined BMI1 mRNA expression in a panel of 8
patient-tumor derived pGBM xenograft models (Table 1),
which were established through direct implantation of
surgical specimens to the matched locations in mouse
brains and strictly subtransplanted in vivo the brains of
SCID mice [45,50]. In 4 of the 8 models in which the
original patient tumors were available, the BMI1 ex-
pression was also examined. Elevated BMI1 mRNA ex-
pression (>1.5 folds of normal adult cerebral tissues)
was observed in 4 models (IC-1406GBM, IC2305GBM,
IC1128GBM and ICb-1227AA); whereas in the remaining
4 models (IC-3704GBM, IC-3752GBM, IC-1621GBM and
IC-1502GBM), low levels of BMI1 mRNA transcripts were
observed (Figure 1B). In all 8 models, relatively stable levels
of BMI1 mRNA expressions were observed during serial
sub-transplantations (from passage I up to V).
To further estimate the relative abundance of BMI1
positive tumor cells, we performed IHC staining. In 4
models (IC-3704GBM, IC-3752GBM, IC-1621GBM, and
IC-1502GBM), low (+) to medium (++) level positivity
was detected, whereas in the remaining 4 models (IC-
1406GBM, IC-2305GBM, IC-1128GBM and ICb-1227AA),
strong (+++) BMI1 expression was observed (Figure 1C).
In all these models, positive reaction was noted in >95% of
tumor cells. Subsequent Western hybridization confirmed
the elevated BMI1 protein expression in all xenograft
Table 1 List of patient tumor-derived orthotopic xenograft mouse models
Model ID Age Gender Diagnosis BMI1 Ref
IC-3704GBM 12 y M GBM (small cell variant) + [50]
IC-3752GBM 5 y F GBM + [50]
IC-1621GBM 6 y M GBM + [50]
IC-1502GBM 4 y 8 mo F GBM (giant cell ) + [50]
IC-1406GBM 5 y F GBM ++ [50]
IC-2305GBM 9 y M GBM (small cell variant) +++ [50]
IC-1128GBM 8 y 7 mo M GBM ++ [45]
ICb-1227AA 16 y 11 mo F Anaplastic Astrocytoma-(radiation induced) ++ [45]
Note: IC: intracerebral; ICb: intracerebellar.
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(obtained from a warm autopsy of an 8-year-old child)
that lacked BMI1 expression (Figure 1D). The overall
findings in Western blot correlated well with the results
obtained from IHC staining, i.e. the xenografts with
low (+) immunoreactivity were found to have weaker
bands and those with high (+++) reactivity exhibited stron-
ger bands. The significance of the smaller molecular weight
band found in IC-1502GBM remains to be determined.
BMI1 expression is not restricted to CD133+ cells
To determine if the expression of BMI1 protein is re-
stricted to CSCs, we isolated CD133+ cells, the most com-
monly used marker to isolate GBM stem cells despite
ongoing controversies [3,51-55], from GBM xenograft tu-
mors and compared their BMI1 protein expression with
CD133− tumor cells. In both CD133+ and CD133− cells de-
rived from 7 GBM xenograft models, nuclear BMI1 ex-
pressions were observed (Figure 1E), suggesting that BMI1
over-expression is not restricted to CD133+ cells.
Silencing BMI1 expression impairs self-renewal growth of
glioma cells in vitro
To evaluate the impact of silencing BMI1 expression on
CSC self-renewal, changes of neurosphere forming effi-
ciency in vitro in serum-free media containing EGF and
bFGF, which is known to favor the growth of CSCs [45],
were evaluated in three models (IC-1406GBM, IC-
2305GBM and ICb-1227AA) that exhibited high levels of
endogenous BMI1. The expression of BMI1 was silenced
using a set of 5 lentiviral shRNAs that were specifically de-
signed to knock down human BMI1. Microscopic examin-
ation revealed significant reduction of neurospheres in
the cells transduced with Lenti-BMI1 shRNA (MOI = 1)
(Figure 2A) as compared with the untreated cells and cells
transduced with non-target shRNA (as mock control).
Subsequent quantitation of cell viability identified Lenti-
693 as the shRNA that produced most significant suppres-
sion of cell proliferation in all three models (Figure 2B)
(P <0.01).To further confirm that the suppressed cell prolifera-
tion was correlated with the silencing of BMI1 gene ex-
pression, changes of BMI1 protein were examined 48 hr
post-lentiviral transduction in CD133+ cells purified with
FACS from xenograft tumors (MOI =1). Compared with
the cells transduced with the non-target shRNA that ex-
hibited similar levels of BMI1 as the untreated cells, cells
transduced with Lenti-BMI1-693 showed remarkable re-
duction of BMI1 protein expression in all three models
(Figure 2C).
Silencing BMI1-abrogated orthotopic xenograft tumor
formation
Previous studies have shown that BMI1 is critical in
maintaining self-renewal of neural stem cells [16-18].
To determine the role of BMI1 in vivo in pGBM stem
cells, we used ABC-conjugated antibodies against hu-
man CD133, the most common cell surface marker of
human glioma stem cells despite the ongoing contro-
versies [4,45,52-54,56-58], to purify CD133+ cells from IC-
2305GBM (the more responsive model) and IC-1406GBM
(the lest responsive model of the three) xenografts. After
these cells were incubated with Lenti-BMI1-693 (MOI =1)
for 48 hr (24 hr in serum-free media followed by an
additional 24 hr selection in media containing puro-
mycin), they were transplanted into the right cerebral
hemisphere of NOD SCID mice (1,500 cells/mouse). The
mice were monitored for up to 425 days. To confirm
tumor growth, whole mouse brains were paraffin embed-
ded, serially sectioned, and stained with hematoxylin-eosin.
Compared with the tumor formation of 33.3% (3 of 9 mice)
and 50% (3 of 6 mice) in the non-target shRNA groups
(CD133 + Lenti-non-target) from IC-1406GBM and IC-
2305GBM, respectively, mice receiving the injection of
CD133 + Lenti-BMI1–693 cells did not form any tumors (0 of
9 mice in IC-1406GBM, and 0 of 7 mice in IC-2305GBM)
(Figure 3A, B). Injection of CD133 + Lenti-BMI1–922 cells re-
sulted in tumor formation of 22.2% (2 of 9 mice) in the IC-
1406GBM group and 0% (0 of 7 mice) in IC-2305GBM,
which is in agreement with our findings in vitro in the
Figure 2 Suppression of neurosphere formation in vitro in pGBM cells by lentivirus-mediated shRNA specific to BMI1. (A) Representative
images showing the suppression of neurosphere formation in two pGBM xenograft models (IC-1206GBM and IC-2305GBM). MTT was added 4 hr
prior to the microscopic examination. Dark-colored intracellular crystal was indicative of viable cells. (B) Graphs showing the quantitative analysis
of cell proliferation (** P < 0.01) in neurospheres derived from 3 independent PDOX models following the silencing of BMI1 with a panel of five
lentivirus-mediated gene-specific shRNAs. O.D. indicates optical density. (C) Western hybridization showing the decreased BMI1 protein expression.
CD133+ cells were purified from 3 PDOX models and transduced with Lenti-BMI1-693 (sh693) for 48 hr before being harvested for protein
extraction. Tumor cells not treated with lentivirus (Control) and transduced with Lentiviruses containing non-target shRNA (Non-target) were
included as references.
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gested that BMI1 is required for the tumor formation of
CD133+ pGBM cells in both models.
Since there are studies suggesting that not all glioma
stem cells are CD133+ and our data indicated that BMI1
was also strongly expressed in CD133− pGBM cells, we
next examined if CD133− pGBM cells were tumorigenic
and if they also depended on BMI1 for tumor formation.
In cells derived from IC-2305GBM, tumor formation
was confirmed in 1 of 9 mice receiving untreated CD133−
cells, and 2 of 9 mice receiving CD133- Lenti-non-target. Since
the injected cell number of CD133− (100,000/mouse) was
far greater than that of the CD133+ cells (1,500/mouse),
this result indicated that the tumor-forming capacity of
CD133− cells was lower than that of the CD133+ cells.
Silencing BMI1 with Lenti-BMI1-693 and −922 led to
complete abrogation of tumor formation in 6 and 7 mice,
respectively. CD133− cells from IC-1406GBM were not
tested due to poor tumor-forming capacity. Combined, our
data demonstrated that silencing the over-expressed BMI1abrogated the tumorigenic capacity of CD133+ cells,
highlighting BMI1 as a potential therapeutic target for
pGBM CSCs.
Understanding the mechanisms of action through gene
expression profiling
To understand the mechanism with which silenced
BMI1 block tumor formation and to identify new down-
stream targets, we performed global gene expression
profiling in paired CD133+ and CD133− cells derived
from 3 models (IC-1406GBM, IC-2305GBM and ICb-
1227AA) that expressed high levels of BMI1 at 48 hrs
post lentiviral transduction. For each sample, RNAs
from 3 sets of cells, 1) untreated control, and cell trans-
duced with 2) non-target Lenti-shRNA, 3) Lenti-BMI1-
693 were extracted and hybridized in duplicate on to
Illumina arrays that contained 48 K elements. To identify
the differentially expressed genes caused specifically by
Lenti-BMI1-693, genes induced by the non-target Lenti-
shRNA (P <0.05 and log2 fold changes >0.5 or < −0.5 when
Figure 3 Elimination of tumor-forming capabilities of CD133+ cells in vivo in mouse brains by Lenti-BMI1-693. (A) Summary of tumor
formation efficiency in tumor cells derived from the two pGBM mouse models. For CD133+ cells, each mouse was implanted with 1,500 cells; and
for the CD133− cells, 100,000 cells/mouse. (B) Representative images of H&E-stained paraffin sections. Compared with huge intracerebral xenografts in
IC-2305GBM cells transduced with non-target Lenti-shRNA, no tumor formation was observed in mice implanted with tumor CD133+ cells in which
BMI1 gene expression was silenced by Lenti-BMI1-693.
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The overall signal intensities of CD133− cells derived from
IC-2305GBM were too low to pass the quality control.
This sample was excluded from the subsequent analysis.
We first examined if BMI1 mRNA expression itself
was affected. When compared with the cells transduced
with the non-target Lenti-shRNA, the mRNA levels of
BMI1 were significantly suppressed by Lenti-BMI1-693
in CD133+ cells from all three 3 models, and the CD133−
cells from ICb-1227AA. The CD133− cells from IC-
1406GBM were the only cells in which the BMI1 mRNA
was not reduced by Lenti-BMI1-693 (Figure 4A). These re-
sults confirmed the silencing effects of Lenti-BMI1-693 on
BMI1 expressions in CD133+ cells, and showed that that
CD133+ and CD133− glioma cells may not have equal re-
sponses toward BMI-1 silencing.
Silencing BMI1 affected different sets of genes in CD133+
and CD133− cells
Given that BMI1 was over-expressed in both CD133+
and CD133− cells, we next examined if silencing BMI1
would affect the same downstream target genes (Figure 4B).
In ICb-1227AA cells transduced by Lenti-BMI1-693, there
were only 25 shared genes, representing 30.8% of 81 differ-
entially expressed genes in CD133+ cells and 19.3% of 129
genes in CD133− cells; whereas in IC-1406GBM, it was
4 of the 111 (3.6%) and 954 (0.4%) genes in CD133+
and CD133− cells, respectively. Findings in IC-1406GBMCD133− cells had to be interpreted with caution as BMI1
expression was not significantly suppressed by Lenti-
BMI1-693 (Figure 4A). Nonetheless, these results demon-
strated that silencing the over-expressed BMI1 affected
different genes in CD133+ and CD133− cells, suggest-
ing that future evaluation of anti-BMI1 therapies should
take into account the biological differences between CSC
(e.g., CD133+ cells) and non-stem (e.g., CD133−) tumor
cells.
Silencing BMI1 did not affect the known target genes
associated with the activated BMI1
We next examined if known BMI1 target genes were af-
fected by silencing BMI1. Mice lacking Bmi1 showed
induction of both p16Ink4a and p19Arf in various
hematopoietic and neuronal tissues [16]. As shown in
Figure 4C, the mRNA levels of CDKN2A (INK4A, P16)
and CDKN2D (INK4D, P19) were not affected, which
was in agreement with previous findings in adult GBM
[28,59]. We also examined Notch1, Gli1, and the 11
gene signature that was previously identified as associ-
ated with the over-expressed BMI1 gene in human ma-
lignant cancers [39] (Figure 4C). In CD133+ cells,
silencing BMI1 did not significantly alter the expression
of 3 genes (ANK3, FGFR2 and CES1) that were down-
regulated by over-expressed BMI1, nor the 8 genes that
were up-regulated by activated BMI1 [39] in any of the 3
GBM models. In CD133− cells, BUB1 was the only gene
Figure 4 Gene expression profiling in pGBM cells. FACS-purified CD133+ and CD133− cells were transduced with Lenti-BMI1-693 for 48 hr in vitro
and harvested for RNA extraction. Tumor cells receiving no or non-target lenti-shRNA were included as control. (A) Down-regulation of BMI1 mRNA in
CD133+ (+) and CD133- (−) cells transduced by Lenti-BMI1-693. For IC-2305GBM, the CD133− cells were not included due to low cell content. (B) List of
gene numbers differentially induced by lentin-BMI1-693 in CD133+ and CD133− cells derived from two PDOX models. Only a small fraction of genes were
shared. (C) Heatmaps of gene expression showing changes of known genes previously associated with the over-expressed BMI1 (left panel) and the new
targets associated with the silencing of BMI1 (right panel). In the known gene panel, those genes originally up-regulated by over-expressed BMI1 are
indicated with up-arrows (↑), and those inhibited by the over-expressed BMI1 are unmarked. No reversal of expression levels were observed in these
genes. In the new target panel, genes consistently altered by Lenti-BMI1-693 in the CD133+ cells from all 3 models are highlighted in the blue
shaded area. Arrows indicate the 4 genes that were validated with qRT-PCR in (D) where the mRNA levels in cells transduced with Lenti-BMI1-693
were normalized with those transduced with Lenti-non-target shRNA and plotted as fold changes (log2).
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log2 scale, P <0.05) in IC-1406GBM (Figure 4C). How-
ever, this gene was originally up-regulated by activatedBMI1 and should have been suppressed. These data indi-
cated that the genes associated with the over-expressed
BMI1 were not reversed following the silencing of BMI1.
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glioma cells
To identify new target genes affected by the silenced
BMI1 in CD133+ glioma cells, we performed a series of
pair-wise comparisons among the 3 models. Our goal
was to identify the core-signature genes that were com-
mon to CD133+ cells. Our comparison of gene expres-
sion profiles of CD133+ cells identified a set of 12 genes
(excluding BMI1) that were significantly down-regulated
(P < 0.05 when compared with Lenti-shRNA, and log2
fold changes < −0.5) in all 3 models by Lenti-BMI1-
693. These included RPS6KA2 (ribosomal protein S6
kinase, 90 kDa, polypeptide 2), API5 (apoptosis in-
hibitor 5), EIF4G2 (eukaryotic translation initiation factor
4 gamma, 2), DTL (denticleless E3 ubiquitin protein ligase
homolog), KIF5C (kinesin family member 5C), ALDH3A2
(aldehyde dehydrogenase 3 family, member A2), GMFB
(glia maturation factor, beta), and 5 less-known genes
(LOC650512, LOC642489, LOC653308, LOC203547, and
C20ORF121) (Figure 4C). Subsequent validation with
qRT-PCR confirmed the down-regulation of RP6KA2,
EIF4G2, API5, and DTL in the cultured CD133+ cells of
these models (Figure 4D). Since none of the aforemen-
tioned genes had been previously identified with BMI1
signaling pathways, our study unraveled a set of genes
that can potentially be the novel target genes in the BMI1
regulatory network in pGBMs. No similar genes were
identified in the CD133− cells derived from the 2 models,
presumably because BMI1 was silenced only in the
CD133− cells in IC-1227AA.
There were an additional 46 genes induced by Lenti-
BMI1-693 in CD133+ cells derived from 2 of the 3 gli-
oma models (Figure 5A). Signaling pathway analysis
identified lanosterol biosynthesis, mTOR signaling, and
cholesterol biosynthesis as the top three pathways af-
fected by Lenti-BMI1-693 (Figure 5B). Because the num-
ber of input genes was relatively low, more studies are
needed to examine the significance of these and the
remaining pathways, such as HIF1α and mitochondria
dysfunction, in the Lenti-BMI1-693 group.
Discussion
In this study, we confirmed the over-expression of BMI1
in a subset of pediatric gliomas, and showed that the
levels of BMI1 mRNA correlated with tumor grade. We
also demonstrated that BMI1 over-expression was main-
tained in a panel of 8 PDOX mouse models. More
importantly, we demonstrated that silencing BMI1 ex-
pression in two independent pGBM models not only led
to significant suppression of cell proliferation and neuro-
sphere formation in vitro, but also caused the abrogation
of xenograft tumor formation in vivo in mouse brains.
Our global gene expression profiling further showed that
silencing BMI1 in the CD133+ cells of pGBM did notaffect the known target genes of the activated BMI1, and
identified a novel set of core genes, including STAU2,
RPS6KA2, ALDH3A2, FMFB, DTL, API5, EIF4G2, KIF5c,
LOC650152, C20ORF121, LOC203547, LOC653308, and
LOC642489, as potential downstream targets of the si-
lenced BMI1 in pGBM.
To gain a relatively accurate estimate of BMI1 gene
expression in pGBM, comparison with age-matched nor-
mal human brain tissue is highly desirable. Recognizing
the difficulties of obtaining normal brain tissue from
children, we utilized the normal fetal brains and normal
adult cerebral RNAs that were commercially available as
references. Although the total number of pediatric gli-
omas that over-expressed BMI1 mRNA varied depend-
ing on the normal references (fetal brain vs. adult brain),
the trend remained the same, i.e. high-grade gliomas
expressed higher levels of BMI1 mRNA than did low-
grade gliomas. These results, combined with our find-
ings in the PDOX mouse models, suggest that BMI1
over-expression might have played an important role in
sustaining tumor growth of high-grade gliomas.
Cancer stem cell hypothesis suggests that only CSCs
have the exclusive self-renewal capacity to form new tu-
mors [3,60,61]. Since BMI1 is an established regulator of
stem cell self-renewal, we focused our studies on CD133+
cells. This is because CD133 remains the most commonly
used human glioma stem cell marker and has been suc-
cessfully applied for the identification and isolation of gli-
oma CSCs, despite ongoing controversies about the
existence of CD133− glioma stem cells [3,4,45,52-54,56-58]
and it role in predicting glioma prognosis and survival
[62-64]. We showed that silencing BMI1 with Lenti-BMI-
693 completely eliminated tumor formation of the CD133+
cells (1,500/mouse) derived from IC-1406GBM and IC-
2305GBM models that over-expressed BMI1. The overall
activities of Lenti-BMI1-693 were the strongest, as it is the
only lenti-BMI1-shRNA that suppressed cell proliferation
in all three glioma models. Altogether, our data demon-
strate that silencing BMI1 is sufficient to eliminate the
tumor-forming capacity of pGBM stem cells in vivo.
Understanding the molecular mechanisms through
which silencing BMI1 led to tumor abrogation is import-
ant for future development of targeted therapies. With
pair-wise comparison of the whole genome gene expres-
sion profiles in FACS fractionated CD133+ and CD133−
tumor cells, we showed that CD133+ and CD133− cells
had distinct responsive genes following the silencing of
BMI1. Identification of such differences between the
matched CD133+ and CD133− cells is important, as it not
only confirms the biological differences between CSC and
non-stem cancer cells, it also suggest that future evaluation
of CSC associated genes/pathways should be performed in
the appropriate cellular types, and data obtained from
bulky tissues should be interpreted with caution.
1227    1406    2305 1227   1406    (Model ID)
CD133+  CD133-
Lenti‐693 Signaling PathwayA B
               ( l I )
  -
Figure 5 Genes differentially altered by lenti-BMI1-693 in CD133+ cells in at least 2 of the 3 PDOX derived cells. (A) Heatmap showing
the 46 genes in CD133+ cells as compared with the CD133− cells. (B) Graph showing the top signaling pathways affected by the silencing of
BMI1 in CD133+ cells.
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target genes previously associated with activated (over-
expressed) BMI1, such as INK4A and ARF and the 11-
gene signature, were not significantly altered. Although
this result might have been caused by the biological dif-
ferences between pGBM and adult cancers or by the
pGBM CSC properties, our intriguing finding may also
reflect the complex nature of gene expression regula-
tions in human cancers. It suggested that the gene expres-
sion changes induced by the activated/over-expressed
BMI1 did not have to alter again if the activated BMI1 is
silenced. Confirmation of this phenomenon in additional
human cancers should impact future development of tar-
geted therapies, as the examination of known “target”
genes - that have previously been associated with the over-
expressed/activated therapeutic target - are frequently
used as additional indicators or diagnostic markers of bio-
logical responses.Our identification of a small set of 13 recurrent genes
provided novel mechanisms through which silencing
BMI1 inhibited pGBM CD133+ cells. These genes were
shared by CD133+ cells derived from all 3 PDOX mouse
models, and many of them have functions critical to the
suppression of tumor formation. For example, down-
regulation of the anti-apoptosis gene API-5 [65-68] may
help to alleviate the anti-apoptosis activities; and inhibition
of EIF4G2 [69] can potentially reverse its suppression of
translation. Inhibition of glia maturation factor (GMFB)
[70,71] and ribosomal protein S6 kinase (RPS6KA2)
[72,73] may be implicated in controlling cell proliferation
and differentiation.
Conclusions
In summary, we demonstrated that BMI1 is over-
expressed in pediatric gliomas, particularly in high-grade
malignant gliomas, in both CD133+ and CD133− cells; and
Baxter et al. Acta Neuropathologica Communications  (2014) 2:160 Page 12 of 14silencing this gene with lentivirus-mediated shRNA led to
elimination of the tumor-forming capacity, particularly
of CD133+ tumor cells, in vivo in two independent and
patient-specific PDOX mouse models, thereby supporting
the development of new targeted therapies against BMI1 in
pGBM. Furthermore, we identified a novel panel of 13
genes that were altered after silencing BMI1, highlighting
the importance of re-analysis of the affected genes follow-
ing the targeted therapy to identify the potential determi-
nants and predicators of efficacy.
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